Owing to the wide range of different tumour subcategories and levels of EGFR expression within basal-like tumours, it is significant that we can demonstrate here the effectiveness of silencing TNK2 even when the EGFR pathway is active but not hyperactivated. This evidence concerns the gene TNK2 and neoplasm.